59084-15-0

Basic information

• Product Name: N-ACETYL-4-(4-CHLOROBENZOYL)-PIPERIDINE
• Synonyms: 1-[4-(4-CHLOROBENZOYL)PIPERIDINO]-1-ETHANONE;N-ACETYL-4-(4-CHLOROBENZOYL)-PIPERIDINE;1-(4-(4-chlorobenzoyl)piperidin-1-yl)ethanone;1-[4-(4-chlorobenzoyl)-1-piperidinyl]ethanone;1-Acetyl-4-(4-chlorobenzoyl)piperidine;Piperidine, 1-acetyl-4-(4-chlorobenzoyl)-
• CAS NO: 59084-15-0
• Molecular Formula: C₁₄H₁₆ClNO₂
• Molecular Weight: 265.74
• Product Categories: Amino Acids & Derivatives;Indole Derivatives
• Mol File: 59084-15-0.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 443.5 °C at 760 mmHg
• Flash Point: 222 °C
• Appearance: Light yellow oil
• Density: 1.22 g/cm³
• Solubility: Chloroform, Dichloromethane, DMF, Methanol
• PKA: -1.60±0.40(Predicted)
• CAS DataBase Reference: N-ACETYL-4-(4-CHLOROBENZOYL)-PIPERIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: N-ACETYL-4-(4-CHLOROBENZOYL)-PIPERIDINE(59084-15-0)
• EPA Substance Registry System: N-ACETYL-4-(4-CHLOROBENZOYL)-PIPERIDINE(59084-15-0)

Safety Data

• Hazardous Substances Data: 59084-15-0(Hazardous Substances Data)

Usage

Chemical Properties

Light Yellow Oil

Uses

Intermediate in the preparation of neuroleptics.

Upstream product

• 59084-16-1 1-acetylpiperidine-4-carbonyl chloride 
• 108-90-7 chlorobenzene 
• 25503-90-6 1-acetyl-piperidine-4-carboxylic acid 
• 498-94-2 isonipecotic acid 

Downstream Products

• 53220-41-0 4-(4-chlorobenzoyl)piperidine 
• 209808-06-0 tert-butyl 4-(4-chlorobenzoyl)piperidine-1-carboxylate 
• 639468-65-8 4-[(4-chlorophenyl)hydroxymethyl]piperidine-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

Synthesis of Novel Aryloxyethylamine Derivatives and Evaluation of Their in Vitro and in Vivo Neuroprotective Activities

A series of aryloxyethylamine derivatives were designed, synthesized and evaluated for their biological activity. Their structures were confirmed by 1H-NMR, 13C-NMR, FT-IR and HR-ESI-MS. The preliminary screening of neuroprotection of compounds in vitro was detected by MTT, and the anti-ischemic activity in vivo was tested using bilateral common carotid artery occlusion in mice. Most of these compounds showed potential neuroprotective effects against the glutamate-induced cell death in differentiated rat pheochromocytoma cells (PC12 cells), especially for (4-fluorophenyl){1-[2-(4-methoxyphenoxy)ethyl]piperidin-4-yl}methanone, {1-[2-(4-methoxyphenoxy)ethyl]piperidin-4-yl}(4-methoxyphenyl)methanone, (4-bromophenyl){1-[2-(4-methoxyphenoxy)ethyl]piperidin-4-yl}methanone, {1-[2-(4-chlorophenoxy)ethyl]piperidin-4-yl}(4-chlorophenyl)methanone, (4-chlorophenyl)(1-{2-[(naphthalen-2-yl)oxy]ethyl}piperidin-4-yl)methanone, (4-chlorophenyl){1-[2-(4-methoxyphenoxy)ethyl]piperidin-4-yl}methanone and {1-[2-(4-bromophenoxy)ethyl]piperidin-4-yl}(4-chlorophenyl)methanone, which exhibited potent protection of PC12 cells at three doses (0.1, 1.0, 10 μM). Compounds (4-fluorophenyl){1-[2-(4-methoxyphenoxy)ethyl]piperidin-4-yl}methanone, (4-fluorophenyl){1-[2-(naphthalen-2-yloxy)ethyl]piperidin-4-yl}methanone, {1-[2-(4-methoxyphenoxy)ethyl]piperidin-4-yl}(4-methoxyphenyl)methanone and {1-[2-(4-chlorophenoxy)ethyl]piperidin-4-yl}(4-chlorophenyl)methanone possessed the significant prolongation of the survival time of mice subjected to acute cerebral ischemia and decreased the mortality rate at all five doses tested (200, 100, 50, 25, 12.5 mg/kg) and had significant neuroprotective activity. In addition, (4-fluorophenyl){1-[2-(4-methoxyphenoxy)ethyl]piperidin-4-yl}methanone, {1-[2-(4-methoxyphenoxy)ethyl]piperidin-4-yl}(4-methoxyphenyl)methanone and {1-[2-(4-chlorophenoxy)ethyl]piperidin-4-yl}(4-chlorophenyl)methanone possessed outstanding neuroprotection in vitro and in vivo. These compounds can be used as a promising neuroprotective agents for future development of new anti-ischemic stroke agents. Basic structure–activity relationships are also presented.

1,4-DlSUBSTITUTED PIPERIDINE DERIVATIVES AND THEIR USE AS 11-BETAHSD1 INHIBITORS

The use of a compound of formula (I) in the manufacture of a medicament for use in the inhibition of 11 betaHSD1 is described.